CSL

CSL’s Vaccine Shock: Stock Plunges to 7-Year Low Amid Shareholder Revolt

Vaccine Slump Triggers Profit Downgrade and 7-Year Share Low CSL – Australia’s fourth-largest public company – stunned the market by cutting its profit outlook and delaying a major spinoff due to a steep and unexpected decline in flu vaccinations in the United States. In an AGM update on Oct. 28, the biotech revealed that U.S. influenza immunization rates are dropping far more than anticipated, undermining its Seqirus vaccine division’s performance reuters.com. CEO Paul McKenzie told shareholders that flu shot uptake in the U.S. was collapsing – a 12% decline in vaccination rates is now expected for the overall population (and 14% for seniors) this season marketscreener.com reuters.com.

28 October 2025

Asia Stocks Rally as Gold Smashes Record Highs and IPO Frenzy Grips Markets

Wall Street Hits Record Highs as ASX Slumps – Gold Crashes, CSL Plunges 15% in Shock Divergence

ASX Sinks Amid Global Cheer Global markets are riding high on hopes of a U.S.–China trade truce and easier monetary policy, but Australia’s share market didn’t get the memo. On Tuesday (Oct 28), the S&P/ASX 200 index closed down 0.5%, surrendering about 43 points to finish near 9,012 abc.net.au. This retreat stands in stark contrast to Wall Street’s overnight rally – U.S. indices surged to record peaks on Monday, buoyed by optimism that President Trump and China’s President Xi will strike a trade deal at an upcoming summit wdio.com. The S&P 500 jumped 1.2% to a historic 6,875, the Dow hit 47,544 (+0.7%) and Nasdaq 23,637

28 October 2025

ASX · Gold Prices · Investment News · Stock Market · Wall Street